BIO vs VTRS · rev $651.0M vs rev $7.27B
BIO (BIO) versus Viatris Inc (VTRS) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Viatris Inc (VTRS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
Latest reported VTRS revenue for 2026-06-30 was $7.27B. VTRS currently screens at market cap $10.83B.
BIO currently screens at market cap $0. VTRS currently screens at market cap $10.83B.
Not investment advice. Open the BIO and VTRS stock pages for the full models.
Not investment advice.